KRK Stock Overview
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €602.00 |
| 52 Week High | €660.00 |
| 52 Week Low | €462.00 |
| Beta | 0.51 |
| 11 Month Change | 1.35% |
| 3 Month Change | 2.03% |
| 1 Year Change | 29.46% |
| 33 Year Change | 7.89% |
| 5 Year Change | 96.09% |
| Change since IPO | 186.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| KRK | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -1.3% | 2.1% | 0.2% |
| 1Y | 29.5% | 49.6% | 0.5% |
Return vs Industry: KRK underperformed the Polish Pharmaceuticals industry which returned 49.6% over the past year.
Return vs Market: KRK exceeded the Polish Market which returned 0.5% over the past year.
Price Volatility
| KRK volatility | |
|---|---|
| KRK Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.4% |
| 10% least volatile stocks in PL Market | 2.9% |
Stable Share Price: KRK has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: KRK's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 11,745 | Jože Colaric | www.krka.si |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular, alimentary tract and metabolism, central nervous system, infections, oncology, and other diseases. The company also provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.
Krka, d. d. Fundamentals Summary
| KRK fundamental statistics | |
|---|---|
| Market cap | zł18.33b |
| Earnings (TTM) | zł1.55b |
| Revenue (TTM) | zł8.21b |
11.8x
P/E Ratio2.2x
P/S RatioIs KRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRK income statement (TTM) | |
|---|---|
| Revenue | €1.90b |
| Cost of Revenue | €825.70m |
| Gross Profit | €1.07b |
| Other Expenses | €714.99m |
| Earnings | €359.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.70 |
| Gross Margin | 56.55% |
| Net Profit Margin | 18.93% |
| Debt/Equity Ratio | 0% |
How did KRK perform over the long term?
See historical performance and comparison